对于图雷特综合征患者使用克隆丁贴片的疗效:一个随机,双盲,安慰剂控制,多中心临床试验

相关实验视频

Updated: Jun 13, 2025

08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.0K

Zhimin Zhao¹, Yun Qian¹, Yasong Du¹

¹Department of Child and Adolescent Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong University, Shanghai.

Clinical neuropharmacology

|September 11, 2024

概括

克洛尼丁粘合贴有效地减少了图雷特综合征 (TS) 的症状. 在临床试验中,更高的1.5和2.0毫克/周剂量显著改善了的严重程度和整体功能.

科学领域:

神经学神经学
临床药理学临床药理学
精神病学是一个精神病学.

背景情况:

图雷特综合征 (TS) 是一种复杂的神经系统疾病,其特征是运动和声部.
目前的TS治疗有局限性,需要探索新的治疗方法.
克洛尼丁粘合剂贴片提供了一种通过皮肤传递的系统,用于管理TS症状.

研究的目的:

评估克洛尼丁粘合贴在患有图雷特综合征的参与者的疗效和安全性.
为了确定克洛尼丁补丁的最佳剂量,用于TS症状管理.

主要方法:

进行了一项随机,双盲,安慰剂控制,多中心的第四期临床试验.
从2012年5月到2015年3月,在20个中心注册了488名TS参与者.
治疗有效性在第8周被评估,以耶鲁全球严重程度尺度作为主要结果衡量标准.

主要成果:

与安慰剂相比,在1.5毫克/周和2.0毫克/周克隆尼丁补丁组观察到耶鲁全球严重性评分的统计学显著下降 (P < 0.001).
与安慰剂相比,每周1.0毫克的组还显示了耶鲁全球严重程度评分总的显著降低 (P <0.001).
二级终点,包括临床全球印象-严重性和改善量表,在所有克隆尼丁组与安慰剂 (所有P<0.001) 之间显示出显著的改善.

结论:

高剂量的克洛尼丁贴片 (1.5和2.0毫克/周) 有效改善图雷特综合征症状.
克洛尼丁补丁在改善TS患者的整体功能方面表现出显著的有效性.
通过皮肤注射的克洛尼丁是治疗图雷特综合征的一种可行的治疗选择.

相关概念视频

01:24

Parkinson's Disease: Treatment

237

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

237

01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

01:24

Cholinergic Antagonists: Pharmacokinetics

423

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...

423

01:18

Patch Clamp

5.4K

Many fundamental cell functions such as muscle contraction and nerve transmission rely on the electrical signals produced by the movement of positively and negatively charged ions across the cell membrane. One competent method to record current flowing across the whole cell or single ion channel is the patch-clamp technique.
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...

5.4K

01:28

Drugs Acting on Autonomic Ganglia: Blockers

979

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:

979

01:23

Drugs Acting on Autonomic Ganglia: Stimulants

1.3K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...